Cargando…

MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison

BACKGROUND: After neoadjuvant therapy, most of the lymph nodes (LNs) will shrink and disappear in patients with rectal cancer. However, LNs that are still detectable on MRI carry a risk of metastasis. This study aimed to evaluate the performance of the European Society of Gastrointestinal and Abdomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhiwen, Chen, Yan, Wen, Ziqiang, Wu, Xuehan, Que, Yutao, Ma, Yuru, Wu, Yunzhu, Liu, Quanmeng, Fan, Wenjie, Yu, Shenping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339540/
https://www.ncbi.nlm.nih.gov/pubmed/37443085
http://dx.doi.org/10.1186/s40644-023-00589-0
_version_ 1785071867323744256
author Zhang, Zhiwen
Chen, Yan
Wen, Ziqiang
Wu, Xuehan
Que, Yutao
Ma, Yuru
Wu, Yunzhu
Liu, Quanmeng
Fan, Wenjie
Yu, Shenping
author_facet Zhang, Zhiwen
Chen, Yan
Wen, Ziqiang
Wu, Xuehan
Que, Yutao
Ma, Yuru
Wu, Yunzhu
Liu, Quanmeng
Fan, Wenjie
Yu, Shenping
author_sort Zhang, Zhiwen
collection PubMed
description BACKGROUND: After neoadjuvant therapy, most of the lymph nodes (LNs) will shrink and disappear in patients with rectal cancer. However, LNs that are still detectable on MRI carry a risk of metastasis. This study aimed to evaluate the performance of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) criterion (short-axis diameter ≥ 5 mm) in diagnosing malignant LNs in patients with rectal cancer after neoadjuvant therapy, and whether nodal morphological characteristics (including shape, border, signal homogeneity, and enhancement homogeneity) could improve the diagnostic efficiency for LNs ≥ 5 mm. METHODS: This retrospective study included 90 patients with locally advanced rectal cancer who underwent surgery after neoadjuvant therapy and performed preoperative MRI. Two radiologists independently measured the short-axis diameter of LNs and evaluated the morphological characteristics of LNs ≥ 5 mm in consensus. With a per node comparison with histopathology as the reference standard, a ROC curve was performed to evaluate the diagnostic performance of the size criterion. For categorical variables, either a χ(2) test or Fisher’s exact test was used. RESULTS: A total of 298 LNs were evaluated. The AUC for nodal size in determining nodal status was 0.81. With a size cutoff value of 5 mm, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 65.9%, 87.0%, 46.8%, 93.6% and 83.9%, respectively. No significant differences were observed in any of the morphological characteristics between benign and malignant LNs ≥ 5 mm (all P > 0.05). CONCLUSIONS: The ESGAR criterion demonstrated moderate diagnostic performance in identifying malignant LNs in patients with rectal cancer after neoadjuvant therapy. It was effective in determining the status of LNs < 5 mm but not for LNs ≥ 5 mm, and the diagnostic efficiency could not be improved by considering nodal morphological characteristics.
format Online
Article
Text
id pubmed-10339540
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103395402023-07-14 MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison Zhang, Zhiwen Chen, Yan Wen, Ziqiang Wu, Xuehan Que, Yutao Ma, Yuru Wu, Yunzhu Liu, Quanmeng Fan, Wenjie Yu, Shenping Cancer Imaging Research Article BACKGROUND: After neoadjuvant therapy, most of the lymph nodes (LNs) will shrink and disappear in patients with rectal cancer. However, LNs that are still detectable on MRI carry a risk of metastasis. This study aimed to evaluate the performance of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) criterion (short-axis diameter ≥ 5 mm) in diagnosing malignant LNs in patients with rectal cancer after neoadjuvant therapy, and whether nodal morphological characteristics (including shape, border, signal homogeneity, and enhancement homogeneity) could improve the diagnostic efficiency for LNs ≥ 5 mm. METHODS: This retrospective study included 90 patients with locally advanced rectal cancer who underwent surgery after neoadjuvant therapy and performed preoperative MRI. Two radiologists independently measured the short-axis diameter of LNs and evaluated the morphological characteristics of LNs ≥ 5 mm in consensus. With a per node comparison with histopathology as the reference standard, a ROC curve was performed to evaluate the diagnostic performance of the size criterion. For categorical variables, either a χ(2) test or Fisher’s exact test was used. RESULTS: A total of 298 LNs were evaluated. The AUC for nodal size in determining nodal status was 0.81. With a size cutoff value of 5 mm, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 65.9%, 87.0%, 46.8%, 93.6% and 83.9%, respectively. No significant differences were observed in any of the morphological characteristics between benign and malignant LNs ≥ 5 mm (all P > 0.05). CONCLUSIONS: The ESGAR criterion demonstrated moderate diagnostic performance in identifying malignant LNs in patients with rectal cancer after neoadjuvant therapy. It was effective in determining the status of LNs < 5 mm but not for LNs ≥ 5 mm, and the diagnostic efficiency could not be improved by considering nodal morphological characteristics. BioMed Central 2023-07-13 /pmc/articles/PMC10339540/ /pubmed/37443085 http://dx.doi.org/10.1186/s40644-023-00589-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zhang, Zhiwen
Chen, Yan
Wen, Ziqiang
Wu, Xuehan
Que, Yutao
Ma, Yuru
Wu, Yunzhu
Liu, Quanmeng
Fan, Wenjie
Yu, Shenping
MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
title MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
title_full MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
title_fullStr MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
title_full_unstemmed MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
title_short MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
title_sort mri for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339540/
https://www.ncbi.nlm.nih.gov/pubmed/37443085
http://dx.doi.org/10.1186/s40644-023-00589-0
work_keys_str_mv AT zhangzhiwen mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT chenyan mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT wenziqiang mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT wuxuehan mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT queyutao mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT mayuru mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT wuyunzhu mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT liuquanmeng mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT fanwenjie mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison
AT yushenping mrifornodalrestagingafterneoadjuvanttherapyinrectalcancerwithhistopathologiccomparison